Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATEC Alphatec	$11.35 +4.5%	$11.84	$4.88 ▼ $13.14	$1.59B	1.1	2.06 million shs	1.67 million shs
ATRC AtriCure	$32.74 +2.6%	$32.51	$20.20 ▼ $43.11	$1.58B	1.59	620,987 shs	223,518 shs
IART Integra LifeSciences	$11.87 +2.2%	$13.69	$11.06 ▼ $32.66	$903.02M	1.16	1.00 million shs	1.52 million shs
NUVA NuVasive	$39.75	$39.64	$35.17 ▼ $49.53	$2.08B	1.07	1.16 million shs	N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATEC Alphatec	+4.51%	+4.61%	-8.84%	+10.73%	+14.30%
ATRC AtriCure	+2.63%	+0.43%	+0.09%	-2.62%	+48.62%
IART Integra LifeSciences	+2.15%	-2.30%	-3.50%	-45.60%	-60.21%
NUVA NuVasive	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATEC Alphatec	4.4084 of 5 stars	3.4	3.0	0.0	3.3	2.3	4.2	0.6
ATRC AtriCure	3.7037 of 5 stars	4.5	3.0	0.0	0.0	2.6	2.5	0.6
IART Integra LifeSciences	4.4075 of 5 stars	3.9	1.0	0.0	4.0	1.1	1.7	2.5
NUVA NuVasive	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATEC Alphatec	2.89	Moderate Buy	$17.89	57.61% Upside
ATRC AtriCure	3.00	Buy	$50.67	54.75% Upside
IART Integra LifeSciences	1.78	Reduce	$18.63	56.91% Upside
NUVA NuVasive	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NUVA, ATEC, ATRC, and IART Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ATEC Alphatec	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$18.00
5/9/2025	IART Integra LifeSciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$35.00 ➝ $25.00
5/6/2025	IART Integra LifeSciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $13.00
5/6/2025	IART Integra LifeSciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$24.00 ➝ $12.00
5/2/2025	ATEC Alphatec	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$13.00 ➝ $15.00
5/2/2025	ATEC Alphatec	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/30/2025	ATRC AtriCure	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$60.00 ➝ $60.00
4/30/2025	ATRC AtriCure	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $58.00
4/30/2025	ATRC AtriCure	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
4/14/2025	ATEC Alphatec	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/11/2025	IART Integra LifeSciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$26.00 ➝ $19.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATEC Alphatec	$611.56M	2.71	N/A	N/A	($0.10) per share	-113.50
ATRC AtriCure	$465.31M	3.48	N/A	N/A	$9.46 per share	3.46
IART Integra LifeSciences	$1.61B	0.57	$4.55 per share	2.61	$20.03 per share	0.59
NUVA NuVasive	$1.23B	1.70	$4.96 per share	8.01	$17.02 per share	2.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATEC Alphatec	-$162.12M	-$1.15	N/A	N/A	N/A	-25.77%	-1,657.19%	-21.53%	7/30/2025 (Estimated)
ATRC AtriCure	-$44.70M	-$0.81	N/A	N/A	N/A	-7.95%	-5.68%	-4.34%	7/29/2025 (Estimated)
IART Integra LifeSciences	-$6.94M	-$0.38	N/A	4.75	0.65	-1.78%	12.12%	4.58%	8/4/2025 (Estimated)
NUVA NuVasive	$40.41M	$0.50	79.50	15.35	N/A	2.32%	12.17%	4.88%	N/A

Latest NUVA, ATEC, ATRC, and IART Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	IART Integra LifeSciences	$0.43	$0.41	-$0.02	-$0.33	$381.17 million	$382.65 million
5/1/2025	Q1 2025	ATEC Alphatec	-$0.12	-$0.35	-$0.23	-$0.35	$167.57 million	$169.18 million
4/29/2025	Q1 2025	ATRC AtriCure	-$0.25	-$0.14	+$0.11	-$0.14	$122.92 million	$123.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATEC Alphatec	N/A	N/A	N/A	N/A	N/A
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
IART Integra LifeSciences	N/A	N/A	N/A	N/A	N/A
NUVA NuVasive	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATEC Alphatec	N/A	2.75	1.67
ATRC AtriCure	0.16	4.11	2.88
IART Integra LifeSciences	0.81	1.21	0.72
NUVA NuVasive	0.50	1.25	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATEC Alphatec	66.35%
ATRC AtriCure	99.11%
IART Integra LifeSciences	84.78%
NUVA NuVasive	N/A

Insider Ownership

Company	Insider Ownership
ATEC Alphatec	22.80%
ATRC AtriCure	3.50%
IART Integra LifeSciences	3.54%
NUVA NuVasive	0.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATEC Alphatec	700	146.17 million	112.85 million	Optionable
ATRC AtriCure	1,300	49.51 million	47.77 million	Optionable
IART Integra LifeSciences	4,396	77.71 million	74.96 million	Optionable
NUVA NuVasive	3,000	52.45 million	52.17 million	Optionable

NUVA, ATEC, ATRC, and IART Headlines

Recent News About These Companies

Analysts downgrade Globus Medical on fears of ‘foundational cracks’

May 27, 2025 | massdevice.com

BTIG Downgrades Globus Medical (GMED) to Neutral on Spine Business Concerns

May 27, 2025 | msn.com

Globus Medical Q1 sales dip slightly: 5 notes

May 10, 2025 | beckersspine.com

Verdict Against NuVasive in Patent Dispute

May 9, 2025 | ryortho.com

5 patent battles to know

May 2, 2025 | beckersasc.com

NuVasive infringed surgeon’s spine patents, jury says

April 24, 2025 | beckersspine.com

Artificial Tendons and Ligaments Market Expected to Hit USD 2.7 Billion by 2035 with a Remarkable 10.46% CAGR

April 23, 2025 | biznes.newseria.pl

NuVasive Infringes Surgeon’s Spinal-Screws Patents, Jury Says

April 22, 2025 | news.bloomberglaw.com

Spine company names Keith Valentine CEO

April 11, 2025 | beckersspine.com

The Perils of Procedural Misadventure and Unclear Claim Drafting in Patent Litigation

March 26, 2025 | jdsupra.com

Global Medical Handily Beats 2024 Sales Estimates

March 14, 2025 | ryortho.com

Globus Medical targets $2.8B-$2.9B revenue in 2025 with Nevro acquisition integration

February 21, 2025 | msn.com

Globus Medical Q4, 2024 sales rise

February 20, 2025 | beckersspine.com

Globus Medical: Some Caution After Its Deal For Nevro

February 16, 2025 | seekingalpha.com

Florida Sales Rep Ordered to Pay $19 million

February 10, 2025 | ryortho.com

Globus acquisition of Nevro complicates story, says Stifel

February 6, 2025 | markets.businessinsider.com

BTIG maintains $91 target on Globus Medical stock post-acquisition

February 6, 2025 | msn.com

SMAIO Provides Update on Its Partnership With NuVasive and Confirms Its Strategic Focus on the U.S. Market

January 28, 2025 | uk.finance.yahoo.com

NuVasive, SMAIO end orthopedic partnership

January 28, 2025 | beckersspine.com

Globus Medical raises FY24 revenue view to $2.52B from $2.49B-$2.5B

January 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVA, ATEC, ATRC, and IART Company Descriptions

Alphatec NASDAQ:ATEC

$11.35 +0.49 (+4.51%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$11.34 0.00 (-0.04%)

As of 06/24/2025 05:48 PM Eastern

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

AtriCure NASDAQ:ATRC

$32.74 +0.84 (+2.63%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$32.74 0.00 (0.00%)

As of 06/24/2025 04:38 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Integra LifeSciences NASDAQ:IART

$11.87 +0.25 (+2.15%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$11.84 -0.03 (-0.26%)

As of 06/24/2025 07:52 PM Eastern

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

NuVasive NASDAQ:NUVA

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time